SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

ROSSI, Silvia Maria Gomes de et al. Impacto da terapia antirretroviral conforme diferentes consensos de tratamento da Aids no Brasil. Rev Panam Salud Publica [online]. 2012, vol.32, n.2, pp. 117-123. ISSN 1020-4989.  http://dx.doi.org/10.1590/S1020-49892012000800005.

    1. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, S0rensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146(2):87-95. [ Links ]

    2. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F; ATHENA national observational cohort study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24(10):1527-35. [ Links ]

    3. Menesia EO, Passos AD, Monteiro ME, Dal-Fabbro AL, Laprega MR. Sobrevivência de pacientes com aids em uma cidade do sudeste brasileiro. Rev Panam Salud Publica. 2001;10(1):29-36. [ Links ]

    4. Estados Unidos da América, National Institute of Allergy and Infectious Diseases. Bethesda, MD: ACTG 106: AZT/ddc combination shows benefits for patients with advanced HIV disease. Disponível em: http://aidsinfo.nih.gov/news/42/actg-106-azt-ddccombination-shows-benefits-for-patientswith-advanced-hiv-disease/ Acessado em 22 de junho de 2008. [ Links ]

    5. Cunningham WE, Markson LE, Andersen RM, Crystal SH, Fleishman JA, Golin C, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. J Acquir Immune Defic Syndr. 2000;25(2):115-23. [ Links ]

    6. Marins JRP, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, et al. Dramatic improvement in survival among Brazilian AIDS patients. AIDS. 2003;17(11):1675-82. [ Links ]

    7. Brasil. Ministério da Saúde. Recomendações para terapia anti-retroviral em adultos e adolescentes infectados pelo hiv - 2001. Brasília, DF. Disponível em: http://www.aids.gov.br/sites/default/files/Consenso_ARV_adulto_-_versao_2001.pdf Acessado em 20 de novembro de 2006. [ Links ]

    8. Reis AC, Santos EM, Cruz MM. A mortalidade por aids no Brasil: um estudo exploratório de sua evolução temporal. Epidemiol Serv Saúde. 2007;16(3):193-205. [ Links ]

    9. Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-nalve persons from 1990 to 2006. Clin Infect Dis. 2007;45(10):1369-74. [ Links ]

    10. Brasil. Ministério da Saúde. Boletim Epidemiológico 2007. Brasília, DF. Disponível em: http://www.aids.gov.br/sites/default/files/Boletim2007_internet090108.pdf Acessado em 22 de novembro de 2007. [ Links ]

    11. Smith CJ, Staszewski S, Sabin C, Nelson M, Dauer B, Gute P, et al. Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1 positive individuals. J Acquir Immune Defic Syndr. 2004;37(1):1155-9. [ Links ]

    12. Fonseca MG, Bastos FI, Derrico M, Andrade CLT, Travassos C, Szwarcwald CL. Aids e grau de escolaridade no Brasil: evolução temporal de 1986 a 1996. Cad Saude Publica. 2000;16(Supl 1):77-87. [ Links ]

    13. Bertoni RF, Bunn K, Silva J, Tracbert J. Perfil demográfico e socioeconómico dos portadores de HIV/AIDS do ambulatório de controle de DST? AIDS de São José, SC. Arq Catarin Med. 2011;4(39):75-9. [ Links ]

    14. Diaz T, Chu SY, Buehler JW, Boyd D, Checko PJ, Conti L, et al. Socioeconomic differences among people with aids: results from a multistate surveillance Project. Am J Prev Med. 1994;10(4):217-22. [ Links ]

    15. Brito AM, Szwarcwald CL, Castilho E. Fatores associados à interrupção de tratamento antirretroviral em adultos com aids. Rio Grande do Norte, Brasil, 1999-2002. Rev Assoc Med Bras. 2006;52(2):86-92. [ Links ]

    16. Santa Helena ET, Mafra ML, Simes M. Fatores associados à sobreviva de pessoas vivendo com aids no Município de Blumenau, Estado de Santa Catarina, Brasil, 1997-2004. Epidemiol Serv Saúde. 2009;18(1):45-53. [ Links ]

    17. Schilkowsky LB, Portela MC, Sá MC. Fatores associados ao abandono de acompanhamento ambulatorial em um serviço de assistência especializada em HIV/aids na cidade do Rio de Janeiro, RJ. Rev Bras Epidemiol. 2011;14(2):187-97. [ Links ]

    18. Brasil. Ministério da Saúde. Boletim Epidemiológico 2008. Brasília, DF. Disponível em: http://www.aids.gov.br/sites/default/files/Boletim2008_versao1_6.pdf Acessado em 10 de dezembro de 2011. [ Links ]

    19. Onem NF, Overton ET, Seyfried W, Stumm ER, Snell M, Mondy K, et al. Aging and HIV infection: a comparison between older HIV infected persons and the general population. HIV Clin Trials. 2010;11(2):100-9. [ Links ]

    20. Escolano Hortelano CM, Ramos Rincón JM, Gutiérrez Rodero F, Masiá Canuto M, Hernández Aguado 1, Benito Santaleocadia C, et al. Cambios en el espectro de la morbilidad y la mortalidad de los ingresos hospitalarios de los pacientes con infección por el virus de la inmunodeficiencia humana durante la era del tratamiento antirretroviral de gran actividad. Med Clin-Barcelona. 2004;122(1):1-5. [ Links ]

    21. Sánchez E, Regidor E, Fuente L, Luquero FJ, Mateo S. Papel del tratamiento antiretroviral en la reducción de la asociación entre nivel educativo bajo y mortalidad por sida. Med Clin-Barcelona. 2008;130(4):133-5. [ Links ]

    22. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50(5):529-36. [ Links ]

    23. Horberg M, Silverberg M, Hurley L, Delorenze G, Quesenberry C. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. 2008;22(4):301-12. [ Links ]

    24. Casseb J, Fonseca LA, Veiga AP, Almeida A, Bueno A, Ferez AC, et al. Aids incidence and mortality on a hospital-based cohort of HIV-1 seropositive patients receiving highly active antiretroviral therapy in São Paulo, Brazil. AIDS Patient Care STDS. 2003;17(9):447-52. [ Links ]

    25. Schneider MF, Gange SJ, Williams CM, Anastos K, Greenblatt RM, Kingsley L, et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1684-2004. AIDS. 2005;19(17):2009-18. [ Links ]

    26. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Muñoz A; Multicenter AIDS Cohort Study. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS. 2001;15(3):347-55. [ Links ]

    27. Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to aids and death in men with known HIV infection duration. JAMA. 1998;280(17):1497-503. [ Links ]

    28. Malta M, Bastos FI, Silva CMFP, Pereira GFM, Lucena FFA, Fonseca MGP, et al. Differential survival benefit of Universal HAART Access in Brazil: a Nation-Wide comparison of injecting drug users versus men who have sex with men. J Acquir Immune Defic Syndr. 2009;52(5):629-35. [ Links ]

    29. Rodríguez-Arenas MA, Jarrín I, del Amo J, Iribarren JA, Moreno S, Viciana P, Peña A, Sirvent JL, Vidal F, Lacruz J, Gutierrez F, Oteo JA, Asencio R, Castilla J, Hoyos SP; CoRIS-MD. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retrov. 2006;22(8):715-23. [ Links ]

    30. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr. 2004;35(1): 46-51. [ Links ]

    31. Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22(17):2371-80. [ Links ]

    32. Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, et al. Characterization of viral dynamics in HIV type 1 infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologie end points. J Infect Dis. 1999;179:799-807. [ Links ]